Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
Monomethyl lithospermate
Catalog No. TN3323Cas No. 933054-33-2
Monomethyl lithospermate (Lithospermic acid monomethyl ester) has potential antiviral activity, alleviating ischemic stroke injury in vivo in middle cerebral artery occlusion mice by activating PI5K/Akt signaling and protecting oxygen-glucose deprivation/reoxygenation-induced SHSY-3Y cells in vitro. Monomethyl lithospermate could improve the viability of SHSY-5Y cells, inhibit mitochondrial membrane potential (MMOP) collapse, and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of middle artery occlusion (MCAO) rats and improved nerve damage in ischemic stroke (IS) rats.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $358 | Backorder | |
| 5 mg | $879 | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Monomethyl lithospermate"
Farrerol
T6S052524211-30-1
1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or act
- $110
Size
QTY
CCT128930
T6303885499-61-6
CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.
- $47
Size
QTY
δ-Tocotrienol
TMA247425612-59-3
δ-Tocotrienol (Delta-Tocotrienol) is a potential angiogenic inhibitor. δ-Tocotrienol is also a nontoxic activator of mir-34a which can inhibit nonsmall cell lung cancer cells (NSC-LC) cell proliferation, induce apoptosis and inhibit invasion, and thus offering a potential starting point for the design of novel anticancer agents.
- $40
Size
QTY
Nyasol
TN468396895-25-9
Nyasol may have potential to be developed as medicines for the treatment of allergies by inhibiting the activation of mast cells. Nyasol shows anti-inflammatory properties by inhibiting iNOS expression; it also has antifungal activity, it is significantly
- $1,790
Size
QTY
Broussonin A
TN353973731-87-0
Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin A shows estrogenic activity with ligand-binding activity of estrogen receptor, transcriptional activity of estrogen-responsive element-luciferase reporter genes. Broussonin A c
- $520
Size
QTY
TASP0415914
T78791292300-75-4
TASP0415914 is an orally potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ). T
- $84
Size
QTY
A-443654
T14072552325-16-3
A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
- $84
Size
QTY
Lenaldekar
T24398418800-15-4
Lenaldekar (LDK) inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis.
- $148
Size
QTY
Vevorisertib trihydrochloride
T388461416775-08-0
Vevorisertib trihydrochloride (ARQ 751 trihydrochloride) is a selective and potent inhibitor of pan-AKT and AKT1-E17K mutations, inhibiting AKT1, AKT2 and AKT3. Vevorisertib trihydrochloride is used in the study of hepatocellular carcinoma and advanced solid tumours.
- $70
Size
QTY
Capivasertib
Cited
T19201143532-39-1
Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.
- $34
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Monomethyl lithospermate (Lithospermic acid monomethyl ester) has potential antiviral activity, alleviating ischemic stroke injury in vivo in middle cerebral artery occlusion mice by activating PI5K/Akt signaling and protecting oxygen-glucose deprivation/reoxygenation-induced SHSY-3Y cells in vitro. Monomethyl lithospermate could improve the viability of SHSY-5Y cells, inhibit mitochondrial membrane potential (MMOP) collapse, and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of middle artery occlusion (MCAO) rats and improved nerve damage in ischemic stroke (IS) rats. |
| In vitro | Monomethyl lithospermate (5, 10 and 20 μM; 12 h) increases cell viability of SHSY-5Y cells treated with oxygen-glucose deprivation and reperfusion (OGD/R).[1] Monomethyl lithospermate (20 μM; 12 h) reduces cell damage, mitochondrial membrane potential loss, and apoptosis in SHSY-5Y cells after hypoxia, glucose deprivation/reoxygenation.[1] Monomethyl lithospermate (5, 10 and 20 μM; 12 h) reduces ROS and intracellular oxidative stress in SHSY-5Y cells.[1] Monomethyl lithospermate (20 μM; 12 h) activates PI3K/AKT in SHSY-5Y cells.[1] |
| In vivo | Monomethyl lithospermate (72.4 μM/kg; oral; once daily for 14 days) improves neurological function and reduces cerebral infarct size in rats with ischemia-reperfusion (IR) 24 h after middle artery occlusion (MCAO); it can reduce MCAO rats reduce oxidative stress levels and inhibit neuronal apoptosis.[1] Monomethyl lithospermate improves ischemia-reperfusion-induced nerve damage by activating PI3K/AKT.[1] |
| Alias | Lithospermic acid monomethyl ester |
| Molecular Weight | 552.48 |
| Formula | C28H24O12 |
| Cas No. | 933054-33-2 |
| Storage | store at low temperature|Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.